2022
Improving DGLA production in soybean for pharmaceutical applications
Contributor/Checkoff:
Category:
Food
Keywords:
Human foodHuman health
Lead Principal Investigator:
Shaobin Zhong, North Dakota State University
Co-Principal Investigators:
Project Code:
QSSB
Contributing Organization (Checkoff):
Institution Funded:
Brief Project Summary:

Scientists are exploring how compounds derived from soybeans could be used to benefit human health. The research team is developing soybeans that can produce oil with higher levels of the fatty acid dihomo-gamma-linolenic acid, or DGLA, to use in certain pharmaceuticals. Researchers at North Dakota State University found that DGLA has inhibitory effects on certain types of cancer cells in mice. But DGLA is not commonly found and a lot is needed to treat cancer. The project looking at developing soybean lines that produce a higher amount of enzymes in order to make DGLA.

Key Benefactors:
farmers, scientists, doctors, soybean breeders

Information And Results
Project Deliverables

Transgenic soybean varieties that produce high DGLA content in oil will be developed for soybean production to meet pharmaceutical industry needs for anti-cancer and anti-aging treatments.

Final Project Results

Updated December 1, 2022:
Improving DGLA production in soybean for pharmaceutical applications

View uploaded report Word file

View uploaded report 2 Word file

The United Soybean Research Retention policy will display final reports with the project once completed but working files will be purged after three years. And financial information after seven years. All pertinent information is in the final report or if you want more information, please contact the project lead at your state soybean organization or principal investigator listed on the project.